Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.

Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Acta Trop. 2018 Feb 13;: Authors: de Moura Ferraz LR, Alves AÉG, da Silva Nascimento DDS, E Amariz IA, Ferreira AS, Costa SPM, Rolim LA, de Lima ÁAN, Neto PJR Abstract Caused by Trypanosoma cruzi, Chagas disease is responsible for public health problems greater in magnitude than those attributed to malaria, schistosomiasis, or leishmaniasis. A factor in the socioeconomic development of poor countries, Chagas disease can cause death due to a high parasitic burden during its acute phase due and irreversible damage in organs such as the heart, esophagus, and colon during its chronic phase, even when the number of parasites is minimal. For treating Chagas disease, benznidazole (BNZ) remains the drug of choice and, in Latin America, the only drug on the market for treating the disease. However, BNZ has exhibited insufficient activity in the chronic phase of Chagas disease, required administration in large doses, prolonged treatment, and shown a high incidence of adverse reactions (vomiting, rash, peripheral neuropathy, and spinal cord depression), toxicity, and low solubility in water. As an antidote, pharmaceutical technologies have been introduced that can improve BNZ's solubility and dissolution, as well as reduce side effects in light of its bioavailability, all of which can enhance therapy for Chagas disease. In response to that ...
Source: Acta Tropica - Category: Infectious Diseases Authors: Tags: Acta Trop Source Type: research